CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that two senior executives will be taking on expanded roles reflecting the Company’s continued growth and plans for commercialization. Ivana Magovcevic-Liebisch, appointed to the position of Executive Vice President of Corporate Development and General Counsel, will also oversee Business Development and Corporate Compliance while continuing to supervise Corporate Communications, Investor Relations and Legal. In addition to directing the Company’s financial strategy and overseeing Accounting and Finance, George Migausky, Executive Vice President and Chief Financial Officer, will also oversee Information Technology and Human Resources.
